[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! View ALL results for your Stocks, ETFs and Funds Screeners with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Black Diamond Therapeutics Inc (BDTX)

Black Diamond Therapeutics Inc (BDTX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 115,177
  • Shares Outstanding, K 57,302
  • Annual Sales, $ 70,000 K
  • Annual Income, $ 22,370 K
  • EBIT $ -46 M
  • EBITDA $ -46 M
  • 60-Month Beta 3.25
  • Price/Sales 1.51
  • Price/Cash Flow 3.49
  • Price/Book 1.01

Options Overview Details

View History
  • Implied Volatility 191.53% (+20.45%)
  • Historical Volatility 153.68%
  • IV Percentile 63%
  • IV Rank 36.12%
  • IV High 435.97% on 03/03/26
  • IV Low 53.32% on 08/19/25
  • Expected Move (DTE 13) 0.24 (11.84%)
  • Put/Call Vol Ratio 0.01
  • Today's Volume 92
  • Volume Avg (30-Day) 231
  • Put/Call OI Ratio 0.14
  • Today's Open Interest 8,299
  • Open Int (30-Day) 15,318
  • Expected Range 1.77 to 2.25

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 10 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/26
See More
  • Average Estimate $-0.18
  • Number of Estimates 5
  • High Estimate $-0.15
  • Low Estimate $-0.22
  • Prior Year $-0.19
  • Growth Rate Est. (year over year) +5.26%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.60 +25.62%
on 06/23/26
2.21 -9.05%
on 06/04/26
-0.17 (-7.80%)
since 06/02/26
3-Month
1.60 +25.62%
on 06/23/26
3.97 -49.37%
on 05/20/26
-0.38 (-15.90%)
since 04/02/26
52-Week
1.60 +25.62%
on 06/23/26
4.94 -59.31%
on 11/12/25
-0.59 (-22.69%)
since 07/02/25

Most Recent Stories

More News
Black Diamond Therapeutics Touts Silevertinib Lung Cancer Data, Eyes FDA Path

Black Diamond Therapeutics (NASDAQ:BDTX) is positioning its lead oncology drug candidate, silevertinib, as a potential treatment for non-small cell lung cancer patients with non-classical EGFR mutations,...

BDTX : 2.01 (+9.24%)
Black Diamond Therapeutics Lung Cancer Drug Shows 15.2-Month PFS in Phase 2 Study

Black Diamond Therapeutics (NASDAQ:BDTX) reported updated Phase 2 data for silevertinib in treatment-naive non-small cell lung cancer patients with EGFR Non-Classical Mutations, saying the investigational...

BDTX : 2.01 (+9.24%)
Black Diamond: Q1 Earnings Snapshot

Black Diamond: Q1 Earnings Snapshot

BDTX : 2.01 (+9.24%)
Black Diamond: Q4 Earnings Snapshot

Black Diamond: Q4 Earnings Snapshot

BDTX : 2.01 (+9.24%)
Black Diamond: Q3 Earnings Snapshot

Black Diamond: Q3 Earnings Snapshot

BDTX : 2.01 (+9.24%)
Black Diamond: Q2 Earnings Snapshot

Black Diamond: Q2 Earnings Snapshot

BDTX : 2.01 (+9.24%)
Black Diamond Therapeutics Shares Jump On New Partnership With France-Based Servier: Retail Sentiment Hits Year-High

As part of the deal, Servier will develop and commercialize the clinical-stage oncology company’s BDTX-4933, a molecule designed to address solid tumors, including non-small cell lung cancer.

BDTX : 2.01 (+9.24%)
VTI : 368.76 (-0.14%)
IWM : 297.58 (-0.58%)
Black Diamond: Q4 Earnings Snapshot

Black Diamond: Q4 Earnings Snapshot

BDTX : 2.01 (+9.24%)
Black Diamond: Q3 Earnings Snapshot

Black Diamond: Q3 Earnings Snapshot

BDTX : 2.01 (+9.24%)
Black Diamond: Q2 Earnings Snapshot

Black Diamond: Q2 Earnings Snapshot

BDTX : 2.01 (+9.24%)

Business Summary

Black Diamond Therapeutics Inc. is an oncology medicine company. It engages in discovery and development of small molecule, tumor-agnostic therapies. The company's lead product candidate is BDTX-189, an inhibitor of non-canonical and oncogenic mutations of ErbB kinases epidermal growth factor receptor...

See More

Key Turning Points

3rd Resistance Point 2.29
2nd Resistance Point 2.16
1st Resistance Point 2.09
Last Price 2.01
1st Support Level 1.88
2nd Support Level 1.75
3rd Support Level 1.68

See More

52-Week High 4.94
Fibonacci 61.8% 3.66
Fibonacci 50% 3.27
Fibonacci 38.2% 2.88
Last Price 2.01
52-Week Low 1.60

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.